Ken Griffin Adaptimmune Therapeutics PLC Put Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Put Options

5 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$0.92 - $1.39 $6,992 - $10,564
-7,600 Reduced 56.72%
5,800 $5,000
Q2 2024

Aug 14, 2024
SELL
$0.83 - $1.47 $12,533 - $22,197
-15,100 Reduced 52.98%
13,400 $13,000
Q1 2024

May 15, 2024
BUY
$0.7 - $1.75 $19,950 - $49,875
28,500 New
28,500 $45,000
Q1 2023

May 15, 2023
SELL
$1.06 - $2.16 $106 - $216
-100 Reduced 3.85%
2,500 $2,000
Q4 2022

Feb 14, 2023
BUY
$1.05 - $2.53 $2,730 - $6,577
2,600 New
2,600 $3,000

Others Institutions Holding ADAP

# of Institutions
82
Shares Held
150M
Call Options Held
60.8K
Put Options Held
5.8K
View Full List

About Adaptimmune Therapeutics PLC

ADAP Quotes by TradingView
  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $108M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email